首页> 美国卫生研究院文献>BMJ Open >Study protocol for a randomised double-blind placebo-controlled clinical trial of duloxetine for the treatment and prevention of musculoskeletal pain: altering the transition from acute to chronic pain (ATTAC pain)
【2h】

Study protocol for a randomised double-blind placebo-controlled clinical trial of duloxetine for the treatment and prevention of musculoskeletal pain: altering the transition from acute to chronic pain (ATTAC pain)

机译:度洛西汀用于治疗和预防肌肉骨骼疼痛的随机双盲安慰剂对照临床试验的研究方案:改变从急性到慢性疼痛(ATTAC疼痛)的转变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionChronic musculoskeletal pain affects a substantial portion of adults visiting the emergency department (ED). Current treatment is limited in scope and does not effectively reduce musculoskeletal pain in patients. The study will evaluate the use of duloxetine, a serotonin-norepinephrine reuptake inhibitor Food and Drug Administration approved for the treatment of chronic pain, as a promising option in its prevention. The proposed study may present a well-tolerated and effective non-opioid treatment for patients with acute musculoskeletal pain that may also be effective in preventing the transition to persistent or chronic musculoskeletal pain.
机译:简介慢性肌肉骨骼疼痛会影响到急诊科(ED)的大部分成年人。目前的治疗方法范围有限,不能有效减轻患者的肌肉骨骼疼痛。该研究将评估食品和药物管理局批准的一种5-羟色胺-去甲肾上腺素再摄取抑制剂度洛西汀在预防慢性疼痛中的应用前景。拟议的研究可能会为急性肌肉骨骼疼痛的患者提供一种耐受良好且有效的非阿片类药物治疗,这也可能有效地预防了向持续性或慢性肌肉骨骼疼痛的转变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号